Explanipedia

Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial Open

Nicholas A. Vitanza, Rebecca Ronsley, Michelle Choe, Kristy Seidel, Wenjun Huang , et al. · 2025

Intracerebroventricular B7-H3 CAR T cells for children and young adults with diffuse intrinsic pontine glioma Open

Nicholas A. Vitanza, Rebecca Ronsley, Michelle Choe, Wenjun Huang, Kristy Seidel , et al. · 2024

Diffuse intrinsic pontine glioma (DIPG) is a fatal central nervous system (CNS) tumor with a median survival of 11 months. Chimeric antigen receptor (CAR) T cells are clinically effective against hematologic malignancies, but there are lim…

Locoregional CAR T Cells for the Treatment of CNS Tumors in Children: Investigational Drug Service Pharmacy Activities. Open

Nicholas A. Vitanza, Michelle Choe, Christopher T. Brown, Adam Beebe, Ada Kong , et al. · 2024

As the field of adoptive immunotherapy grows and continues to bring hope to patients with fatal CNS malignancies, it is critical to focus on improving the preparatory steps for CAR T-cell delivery.

EP30.12: Mature cystic teratoma of the omentum: a case report Open

Ada Kong, Concepción Gómez · 2023

Ovarian cysts are the most common abdominal cyst in the female fetus, with an incidence of 1 in 2600.Applying the IOTA terminology in such cases allows appropriate follow-up to preserve fetal ovarian function in those born with masses with…

Locoregional CAR T cells for children with CNS tumors: Clinical procedure and catheter safety Open

Nicholas A. Vitanza, Rebecca Ronsley, Michelle Choe, Casey Henson, Mandy Breedt , et al. · 2023

Central nervous system (CNS) tumors are the most common solid malignancy in the pediatric population. Based on adoptive cellular therapy's clinical success against childhood leukemia and the preclinical efficacy against pediatric CNS tumor…

Monoclonal Antibody and Antiviral Therapy for Mild-to-Moderate COVID-19 in Pediatric Patients Open

Surabhi B Vora, Janet A. Englund, Indi Trehan, Alpana Waghmare, Ada Kong , et al. · 2022

Multiple antiviral and monoclonal antibody therapies are now available for mild-moderate COVID-19 in high-risk patients ≥12 years of age. However, data for the use of these agents in children is limited. We reviewed 94 pediatric patients f…

Alpelisib for the treatment of PIK3CA-related head and neck lymphatic malformations and overgrowth Open

Tara Wenger, Sheila Ganti, Catherine Bull, Erika Lutsky, James T. Bennett , et al. · 2022

Monoclonal antibody and antiviral therapy for treatment of mild-to-moderate COVID-19 in pediatric patients Open

Surabhi B Vora, Janet A. Englund, Indi Trehan, Alpana Waghmare, Ada Kong , et al. · 2022

The recent surge of SARS-CoV-2 Omicron variant (B.1.1.529) coincided with new treatment options for mild-to-moderate Covid-19 in high-risk adolescents and adults. In this report we describe patient characteristics, treatment-related proces…

Testing the effects of combining azithromycin with inhaled tobramycin for<i>P. aeruginosa</i>in cystic fibrosis: a randomised, controlled clinical trial Open

David P. Nichols, Pradeep K. Singh, Arthur Baines, Lindsay J. Caverly, James F. Chmiel , et al. · 2021

Rationale Inhaled tobramycin and oral azithromycin are common chronic therapies in people with cystic fibrosis and Pseudomonas aeruginosa airway infection. Some studies have shown that azithromycin can reduce the ability of tobramycin to k…

Azithromycin for Early <i>Pseudomonas</i> Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial Open

Nicole Mayer-Hamblett, George Retsch‐Bogart, Margaret Kloster, Frank J. Accurso, Margaret Rosenfeld , et al. · 2018

Azithromycin was associated with a significant reduction in the risk of pulmonary exacerbation and a sustained improvement in weight, but had no impact on microbiological outcomes in children with early Pa. Clinical trial registered with c…

Ada Kong YOU? Author Swipe